Search

Search Constraints

You searched for: Author/Creator Ascierto, P A

Search Results

1. 1159PPhase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. (23rd October 2018)

2. 1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. (23rd October 2018)

3. 1278PHealth-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. (23rd October 2018)

5. 129O Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155. (15th December 2019)

6. 12PMSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies. (17th December 2018)

7. 1306TiPILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. (23rd October 2018)

8. 610TiPPreoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE). (23rd October 2018)

9. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. (30th March 2017)